Dr. David Alan Sweetser, MD

Dr. Sweetser practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Sweetser's NPI, 1558320762, was assigned on March 17, 2006. Dr. Sweetser graduated from WashU Medicine in 1989. Dr. Sweetser holds Massachusetts license 216677.

Dr. Sweetser's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Sweetser's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Sweetser to 1 more community health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sweetser practices, 2 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Sweetser's primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Sweetser is board certified in clinical biochemical genetics by the American Board of Medical Genetics and Genomics. Dmand AI has Dr. Sweetser's licenses on file in 4 states: Massachusetts, Maine, New Hampshire and Rhode Island.

CMS data shows 39 Medicare services from Dr. Sweetser across 1 procedure code in 2024, for 17 Medicare patients. Medicare paid $1,029 for them. Every service was in an office.

CMS counts 17 Medicare patients who saw Dr. Sweetser in 2024. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sweetser's median patient age at 22, with 52% women.

In 2024, Dr. Sweetser wrote 85 Medicare Part D claims. 73% of them were for generic drugs. CMS names the drug for 63 of them, across 3 drugs with 11 or more claims each, at $1,650,320 in total drug cost. In 2023, CMS named 64 claims across 3 drugs.

Dr. Sweetser accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sweetser as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 81 papers to Dr. Sweetser, published from 2003 to 2025. 2016 was the busiest year, with 8. The most frequent topics are Intellectual Disability, Phenotype and Amino Acid Sequence. Dr. Sweetser has published most often in Am J Hum Genet. Dr. Sweetser's most frequent co-authors are Frances Arianwen High, MD, PhD, Joel Brett Krier, MD and Richard Alan Young, MD.

Dmand AI links Dr. Sweetser to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Undiagnosed Diseases and Rare Diseases.

CMS Open Payments shows 10 general payments to Dr. Sweetser from 3 drug and device companies from 2017 to 2022. Consulting fees make up the largest share, 97% of the total. Merck Sharp & Dohme Corporation paid the most, $2,000.

Dmand AI lists 2 awards for Dr. Sweetser, most recently Regional Top Doctor in 2019.

Dr. Sweetser graduated from WashU Medicine in 1989. Dr. Sweetser is a member of AAP.

Dr. Sweetser is in network with 15 carriers, including Blue Cross Blue Shield of Michigan, Elevance and United Healthcare. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.